XML 100 R71.htm IDEA: XBRL DOCUMENT v3.20.4
Subsequent Events (Details)
$ / shares in Units, dose in Millions, $ in Millions
12 Months Ended
Mar. 01, 2021
dose
$ / shares
shares
Feb. 07, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
Feb. 02, 2021
Dec. 31, 2019
$ / shares
May 16, 2019
$ / shares
Subsequent Events            
Price per share (in USD per share)           $ 12.41
Convertible preferred stock, par value (in USD per share)     $ 0.01   $ 0.01  
Registered Direct Offering            
Subsequent Events            
Proceeds from sale of stock | $     $ 21.2      
Subsequent events | Registered Direct Offering            
Subsequent Events            
Number of shares issued and sold | shares   3,000,000.0        
Price per share (in USD per share)   $ 7.65        
Proceeds from sale of stock | $   $ 21.2        
Commissions, fees and expenses | $   $ 1.7        
Subsequent events | COVAXIN Preferred Stock Purchase Agreement            
Subsequent Events            
Profits generated, shared percentage       45.00%    
Subsequent events | COVAXIN Preferred Stock Purchase Agreement | Series B Preferred Stock            
Subsequent Events            
Number of shares agreed to issue and sell | shares 100,000          
Convertible preferred stock, par value (in USD per share) $ 0.01          
Price per share ( in USD per share) $ 109.60          
Shares issued upon conversion (in shares) | shares 10          
Supply Agreement, Number of Doses | dose 10.0